ASN’s guidance helps clinicians and patients with CKD understand the effects of potassium and phosphorus food additives on their health.

Only 16% of fast food entrees are free of phosphorus-containing additives, a study found. They need to know how to identify phosphate additives on food labels. Clinicians attempt to control patients’ ...

Taking phosphate binders may lower the risk of osteoporotic fractures in patients initiating dialysis. Oral phosphate binders may decrease the risk for osteoporotic fracture in patients starting ...

Dialysis is a critical treatment for individuals with kidney failure, helping to filter waste, excess fluids, and toxins from the blood when the kidneys lose their function. While dialysis ...

ISTANBUL, Turkey — The investigational drug PA21 controls hyperphosphatemia over the long term and has a lower pill burden than sevelamer carbonate, according to a phase 3 study. The cardiovascular ...

A group of FDA advisors recommended approval of tenapanor (Ibsrela) for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on dialysis, both as a single agent and in ...

The FDA approved the first-in-class phosphate absorption inhibitor tenapanor (Xphozah) to reduce serum phosphorus in chronic kidney disease (CKD) patients on dialysis, developer Ardelyx announced on ...

Please provide your email address to receive an email when new articles are posted on . An FDA advisory committee voted 9-4 in favor of the use of Xphozah as a monotherapy for controlling serum ...

Sevelamer carbonate 800 mg; tabs. Patients with CKD can develop hyperphosphatemia as a result of retained phosphorus, which may lead to ectopic calcification. Hyperphosphatemia plays a role in the ...